| (Values in U.S. Thousands) | Mar, 2022 | Dec, 2021 | Sep, 2021 | Jun, 2021 | Mar, 2021 |
| Sales | 119,790 | 128,660 | 113,880 | 115,980 | 114,930 |
| Sales Growth | -6.89% | +12.98% | -1.81% | +0.91% | -3.19% |
| Net Income | 1,900 | 1,740 | 5,570 | 3,460 | 2,400 |
| Net Income Growth | +9.20% | -68.76% | +60.98% | +44.17% | -53.85% |
Natus Medical Inc (NTUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories.
Fiscal Year End Date: 12/31